# ICU Medical Inc. (ICUI) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Medical Devices & Supplies. Price $161.83, market value $4.0 billion.

## Valuation
- **P/E (trailing): 136.0×** (5-yr avg 2402.9×, 3-yr avg 4755.7×). ICU Medical Inc. trades at 136.0× trailing earnings, well below its own five-year average of 2402.9×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 16.8×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.17**. A PEG of 0.17 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 1.9×**. Each dollar of revenue is priced at 1.9×.
- **Price / book: 1.9×**. The shares trade at 1.9× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 19.5×**. Enterprise value is 19.5× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 3.8%** (5-yr avg 1.8%). Free cash flow equals 3.8% of the market value, above its five-year average of 1.8%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 0.7%**. The inverse of the P/E: 0.7% of the price is earned each year.

## Profitability
- **Gross margin: 39.1%**. ICU Medical Inc. keeps 39.1% of revenue after the direct cost of what it sells.
- **Operating margin: 3.3%**. 3.3% of revenue is left after running the business, which leaves little cushion in a downturn.
- **Net margin: 0.0%**. 0.0% of each dollar of sales reaches the bottom line.
- **Return on equity: 0.0%**. 0.0% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on invested capital: 1.7%**. Return on all capital, debt included, is 1.7%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: 0.7%**. Each dollar of assets produces 0.7% of profit.

## Growth
- **Revenue growth (1 yr): -6.3%** (3-yr -0.7%/yr, 5-yr 11.9%/yr). Revenue fell 6.3% over the last year, against 11.9% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 100.6%** (5-yr -62.5%/yr). Earnings per share rose 100.6%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.60**. Debt is 0.60 times equity, moderate leverage.
- **Current ratio: 2.39** (quick 2.39). Current assets cover the next year's liabilities 2.39 times.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. ICU Medical Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (8 analysts). 8 analysts cover ICU Medical Inc.; the consensus is buy, with an average price target of $193.38 (+19% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 35.2%** (YTD 13.8%, 3-mo -6.1%). The shares are up 35.2% over twelve months including dividends.
- **From 52-week high: -16.1%** (42.7% above the low). Trading 16% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 48**. An RSI of 48 is neutral.
- **Beta (1 yr): 1.00** (volatility 36%). Beta of 1.00 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ICUI · Page: https://foliofundamentals.com/stocks/icui

Not investment advice.